OPDIVO® (Nivolumab)

The FDA on September 13, 2016 modified the dosage regimen for OPDIVO®, which is currently approved for Renal Cell Carcinoma, metastatic Melanoma, and Non Small Cell Lung Cancer. The currently approved recommended dosage regimens were modified to 240 mg intravenously (IV) every two weeks. OPDIVO® is marketed by Bristol-Myers Squibb company.